{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:12:14Z","timestamp":1790341934959,"version":"4.1.0"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Bromodomain and Extraterminal (BET) proteins play a crucial role in cellular proliferation and differentiation through the epigenetic regulation of gene transcription. As a result, inhibiting BET family proteins emerges as a promising epigenetic approach for treating various cancers. However, clinical trials have indicated that thrombocytopenia is a dose-limiting toxicity associated with BET inhibition. This study aims to explore the mechanism and clinical pharmacology of BMS-986158-induced thrombocytopenia and to identify biomarkers as tools to identify patients at higher risk, thereby better managing toxicity and improving efficacy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Blood samples from preclinical rats and clinical trial patients treated with BMS-986158 were collected for transcriptional expression profiling. Target engagement was confirmed by measuring HEXIM1 and monitoring thrombocytopenia following BET inhibition. Genes regulated by GATA1 and associated with thrombopoiesis, including NFE2 and PF4, were investigated. The outcomes of the rat and human studies were compared to identify biomarkers for the early prediction of thrombocytopenia associated with BET inhibition.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Target engagement was confirmed with dose-dependent responses of HEXIM1 expression and platelet counts. Blood samples from rats treated with BMS-986158 showed dose-dependent downregulation of GATA1, NFE2, and PF4 at 24\u202fh or earlier post-treatment. Similarly, patients\u2019 blood samples collected within 24\u202fh post-treatment with BMS-986158 also showed dose-dependent downregulation of GATA1 and PF4 in all treated groups. Significant downregulation of PF4 and NFE2 genes was found in patients with low platelet counts. A strong correlation between the expression of GATA1 and the genes NFE2 and PF4 was observed in both preclinical and clinical studies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>The consistent downregulation of GATA1, NFE2, and PF4 transcription within hours post-BMS-986158 treatment in both preclinical and clinical studies demonstrates that BET inhibitors induce thrombocytopenia by altering GATA1 gene expression and its downstream genes, NFE2 and PF4, which regulate megakaryopoiesis and thrombopoiesis. Early detection of transcriptional changes in blood samples during treatment courses positions NFE2 and PF4 as promising biomarkers for proactively monitoring and mitigating treatment-emergent thrombocytopenia.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1592693","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T14:47:15Z","timestamp":1756306035000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["NFE2 and PF4 as biomarkers for BET inhibition-induced thrombocytopenia in preclinical and clinical studies"],"prefix":"10.3389","volume":"12","author":[{"given":"Cindy","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faye","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Panzica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shodeinde","family":"Coker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriana","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Greenawalt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Westhouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Augustine-Rauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,27]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"Bet bromodomain inhibition as a therapeutic strategy to target c-Myc","volume":"146","author":"Delmore","year":"2011","journal-title":"Cell"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1093\/annonc\/mdx157","article-title":"Bet inhibitors: a novel epigenetic approach","volume":"28","author":"Doroshow","year":"2017","journal-title":"Ann Oncol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/nrm3931","article-title":"50 years of protein acetylation: from gene regulation to epigenetics, metabolism and beyond","volume":"16","author":"Verdin","year":"2015","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"d447","DOI":"10.2741\/a291","article-title":"Role of E2F in cell cycle control and cancer","volume":"3","author":"Johnson","year":"1998","journal-title":"Front Biosci"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.molcel.2005.06.027","article-title":"The bromodomain protein Brd4 is a positive regulatory component of P-Tefb and stimulates Rna polymerase ii-dependent transcription","volume":"19","author":"Jang","year":"2005","journal-title":"Mol Cell"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"13141","DOI":"10.1074\/jbc.R700001200","article-title":"The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation","volume":"282","author":"Wu","year":"2007","journal-title":"J Biol Chem"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"6380","DOI":"10.1073\/pnas.0710331105","article-title":"Bromodomain 4 activation predicts breast cancer survival","volume":"105","author":"Crawford","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"9491","DOI":"10.18632\/oncotarget.7068","article-title":"High level of Brd4 promotes non-small cell lung cancer progression","volume":"7","author":"Liao","year":"2016","journal-title":"Oncotarget"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1016\/j.celrep.2017.05.049","article-title":"Androgen receptor deregulation drives Bromodomain-mediated chromatin alterations in prostate Cancer","volume":"19","author":"Urbanucci","year":"2017","journal-title":"Cell Rep"},{"key":"ref10","first-page":"304","article-title":"Brd4-nut fusion oncogene: a novel mechanism in aggressive carcinoma","volume":"63","author":"French","year":"2003","journal-title":"Cancer Res"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1038\/sj.onc.1210852","article-title":"Brd-nut oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells","volume":"27","author":"French","year":"2008","journal-title":"Oncogene"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"14247","DOI":"10.1021\/acs.jmedchem.1c00625","article-title":"Discovery and preclinical pharmacology of an oral bromodomain and extra-terminal (bet) inhibitor using scaffold-hopping and structure-guided drug design","volume":"64","author":"Gavai","year":"2021","journal-title":"J Med Chem"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3390\/cancers14174079","article-title":"BMS-986158, a small molecule inhibitor of the bromodomain and extraterminal domain proteins, in patients with selected advanced solid tumors: results from a phase 1\/2a trial","volume":"14","author":"Hilton","year":"2022","journal-title":"Cancers (Basel)"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"5789","DOI":"10.1158\/1538-7445.AM2018-5789","article-title":"Abstract 5789: discovery of clinical candidate Bms-986158, an oral bet inhibitor, for the treatment of cancer","volume":"78","author":"Gavai","year":"2018","journal-title":"Cancer Res"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"5792","DOI":"10.1158\/1538-7445.AM2018-5792","article-title":"Abstract 5792: preclinical antitumor activity of BMS-986158, an oral bet inhibitor, for the treatment of cancer","volume":"78","author":"Wee","year":"2018","journal-title":"Cancer Res"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/nature09504","article-title":"Selective inhibition of bet bromodomains","volume":"468","author":"Filippakopoulos","year":"2010","journal-title":"Nature"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ejca.2018.12.020","article-title":"First-in-human phase I study of the bromodomain and extraterminal motif inhibitor bay 1238097: emerging pharmacokinetic\/pharmacodynamic relationship and early termination due to unexpected toxicity","volume":"109","author":"Postel-Vinay","year":"2019","journal-title":"Eur J Cancer"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"621093","DOI":"10.3389\/fphar.2020.621093","article-title":"Safety and efficacy of bromodomain and extra-terminal inhibitors for the treatment of hematological malignancies and solid tumors: a systematic study of clinical trials","volume":"11","author":"Sun","year":"2020","journal-title":"Front Pharmacol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1158\/1078-0432.CCR-22-1284","article-title":"A phase I\/ii open-label study of Molibresib for the treatment of relapsed\/refractory hematologic malignancies","volume":"29","author":"Dawson","year":"2023","journal-title":"Clin Cancer Res"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"6309","DOI":"10.1158\/1078-0432.CCR-19-0578","article-title":"First-in-human study of mivebresib (Abbv-075), an oral pan-inhibitor of bromodomain and extra terminal proteins, in patients with relapsed\/refractory solid tumors","volume":"25","author":"Piha-Paul","year":"2019","journal-title":"Clin Cancer Res"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1182\/blood-2014-10-607309","article-title":"Functions of bet proteins in erythroid gene expression","volume":"125","author":"Stonestrom","year":"2015","journal-title":"Blood"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1159\/000086586","article-title":"Dyserythropoietic anemia and thrombocytopenia due to a novel mutation in Gata-1","volume":"114","author":"Del Vecchio","year":"2005","journal-title":"Acta Haematol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"22385","DOI":"10.1074\/jbc.M500081200","article-title":"Graded levels of Gata-1 expression modulate survival, proliferation, and differentiation of erythroid progenitors","volume":"280","author":"Pan","year":"2005","journal-title":"J Biol Chem"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1093\/emboj\/16.13.3965","article-title":"A lineage-selective knockout establishes the critical role of transcription factor Gata-1 in megakaryocyte growth and platelet development","volume":"16","author":"Shivdasani","year":"1997","journal-title":"EMBO J"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1101\/gad.9.10.1250","article-title":"Gata-1 reprograms avian myelomonocytic cell lines into eosinophils, thromboblasts, and erythroblasts","volume":"9","author":"Kulessa","year":"1995","journal-title":"Genes Dev"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2302\/kjm.60.47","article-title":"Role of transcription factors in differentiation and reprogramming of hematopoietic cells","volume":"60","author":"Nakajima","year":"2011","journal-title":"Keio J Med"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1002\/ajh.23682","article-title":"Iron deficiency alters megakaryopoiesis and platelet phenotype independent of thrombopoietin","volume":"89","author":"Evstatiev","year":"2014","journal-title":"Am J Hematol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"36609","DOI":"10.1074\/jbc.M112.410746","article-title":"Bromodomain and extra-terminal (bet) bromodomain inhibition activate transcription via transient release of positive transcription elongation factor b (P-Tefb) from 7sk small nuclear ribonucleoprotein","volume":"287","author":"Bartholomeeusen","year":"2012","journal-title":"J Biol Chem"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/1535-7163.MCT-16-0475","article-title":"Hexim1 as a robust Pharmacodynamic marker for monitoring target engagement of bet family Bromodomain inhibitors in tumors and surrogate tissues","volume":"16","author":"Lin","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1038\/sj.emboj.7600275","article-title":"Binding of the 7sk snRNA turns the Hexim1 protein into a P-Tefb (Cdk9\/cyclin T) inhibitor","volume":"23","author":"Michels","year":"2004","journal-title":"EMBO J"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"viii134","DOI":"10.1093\/annonc\/mdy279.399","article-title":"Initial results from a phase I\/IIa trial evaluating BMS-986158, an inhibitor of the bromodomain and extra-terminal (BET) proteins, in patients (pts) with advanced cancer","volume":"29","author":"Hilton","year":"2018","journal-title":"Ann Oncol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1182\/blood.V76.2.336.336","article-title":"Structural and functional comparison of the genes for human platelet factor 4 and Pf4alt","volume":"76","author":"Eisman","year":"1990","journal-title":"Blood"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/j.1365-2141.1990.tb06325.x","article-title":"Negative regulation of human megakaryocytopoiesis by human platelet factor 4 and beta thromboglobulin: comparative analysis in bone marrow cultures from normal individuals and patients with essential thrombocythaemia and immune thrombocytopenic purpura","volume":"74","author":"Han","year":"1990","journal-title":"Br J Haematol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1182\/blood-2016-09-687889","article-title":"Gata factor mutations in hematologic disease","volume":"129","author":"Crispino","year":"2017","journal-title":"Blood"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1182\/blood-2011-04-285981","article-title":"Transcription factor networks in erythroid cell and megakaryocyte development","volume":"118","author":"Dore","year":"2011","journal-title":"Blood"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1182\/blood.2020009300","article-title":"Genetics of inherited thrombocytopenias","volume":"139","author":"Warren","year":"2022","journal-title":"Blood"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1182\/blood.v98.9.2681","article-title":"X-linked thrombocytopenia caused by a novel mutation of Gata-1","volume":"98","author":"Mehaffey","year":"2001","journal-title":"Blood"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1182\/blood.V116.21.741.741","article-title":"Dynamic co-localization of Gata1, Nfe2, and Eklf and changes in gene expression during hematopoiesis","volume":"116","author":"Steiner","year":"2010","journal-title":"Blood"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/978-3-031-62731-6_12","article-title":"Gata1 in Normal and pathologic Megakaryopoiesis and platelet development","volume":"1459","author":"Takasaki","year":"2024","journal-title":"Adv Exp Med Biol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"10444","DOI":"10.1073\/pnas.89.21.10444","article-title":"Functional erythroid promoters created by interaction of the transcription factor Gata-1 with Caccc and Ap-1\/Nfe-2 elements","volume":"89","author":"Walters","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"6944","DOI":"10.1093\/nar\/gkr253","article-title":"The distinctive roles of erythroid specific activator Gata-1 and Nf-E2 in transcription of the human fetal gamma-globin genes","volume":"39","author":"Woon Kim","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1182\/bloodadvances.2018021865","article-title":"Nfe2 is dispensable for early but required for adult thrombocyte formation and function in zebrafish","volume":"2","author":"Rost","year":"2018","journal-title":"Blood Adv"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.3324\/haematol.2019.244541","article-title":"Oncogenic Gata1 causes stage-specific megakaryocyte differentiation delay","volume":"106","author":"Juban","year":"2021","journal-title":"Haematologica"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"3928","DOI":"10.1182\/blood-2024-208624","article-title":"Chromatin remodeling by Gata1s alters megakaryocytic gene expression","volume":"144","author":"De Castro","year":"2024","journal-title":"Blood"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1158\/2767-9764.CRC-22-0060","article-title":"A phase I study of Pelabresib (Cpi-0610), a small-molecule inhibitor of bet proteins, in patients with relapsed or refractory lymphoma","volume":"2","author":"Blum","year":"2022","journal-title":"Cancer Res Commun"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1182\/blood-2016-11-752840","article-title":"Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis","volume":"130","author":"Machlus","year":"2017","journal-title":"Blood"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1158\/1538-7445.AM2021-1951","article-title":"Smac mimetic and bet inhibitor - a promising combination for solid cancer treatment","volume":"81","author":"Traexler","year":"2021","journal-title":"Cancer Res"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ccell.2017.11.009","article-title":"Dual targeting of oncogenic activation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms","volume":"33","author":"Kleppe","year":"","journal-title":"Cancer Cell"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1182\/blood-2018-03-839779","article-title":"Jak 2 and Jmjd1C. Activate Nfe2 in Mpns","volume":"131","author":"Crispino","year":"2018","journal-title":"Blood"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1182\/blood.2020010402","article-title":"Impact of Nfe2 mutations on Aml transformation and overall survival in patients with myeloproliferative neoplasms","volume":"138","author":"Marcault","year":"2021","journal-title":"Blood"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1592693\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T14:47:17Z","timestamp":1756306037000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1592693\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":50,"alternative-id":["10.3389\/fmed.2025.1592693"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1592693","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,27]]},"article-number":"1592693"}}